Print

Sigma-Aldrich Corporation (SIAL) Signs Licensing Agreement With Epigentek Group Inc.  
6/12/2007 11:58:02 AM

ST. LOUIS, June 12 /PRNewswire-FirstCall/ -- Sigma-Aldrich is pleased to announce it has signed a licensing agreement with Epigentek Group, Inc. to further develop and commercialize technologies for Epigenetics research (http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/Epigenetics.html) Under this agreement, Sigma-Aldrich gains rights to core Epigentek technologies, including DNA modification, methylation quantitation and protein/DNA interaction. This agreement is exclusive in the U.S. and co-exclusive globally.

"Sigma-Aldrich has identified Epigenetics as a growing area of interest and research for heritable diseases such as cancer, Alzheimer's and many others," said Keith Jolliff, Director of Genomics and Functional Genomics at Sigma-Aldrich. "We see the licensing with Epigentek as the right fit to our ongoing commitment to provide best-in-class solutions to the research community and an excellent entry point to supporting Epigenetics research."

Sigma-Aldrich plans to launch a family of products for Epigenetic research, beginning with the Imprint DNA Modification Kit (http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/Epigenetics.html) in June 2007. The Company aims to provide customers a complete Epigenetic solution from DNA purification and bisulfite conversion to detection. Other products launching under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek's technologies.

Epigentek offers the most sensitive, reliable and fastest procedures for Bisulfite DNA modification and chromatin immunoprecipitation. Their proprietary DNA modification technology provides DNA conversion for methylation analysis in less than two hours and requires only 50 picograms of starting DNA. For more information on products to support the Epigenetic workflow, visit http://www.sigma.com/epigenetics.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Photo: http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSigma-Aldrich

CONTACT: Sean Battles, +1-314-286-7616, sean.battles@sial.com, ofSigma-Aldrich


//-->